Garcia-Cuesta C, Sarrion-Pérez
MG, Bagan JV. Current treatment of oral candidiasis: a
literature review. J Clin Exp Dent.
2014;6(5):e576-82.
doi:10.4317/jced.51798
References
1. Arendrup
MC, Fuursted K, Gahrn-Hansen
B, Jensen IM, Knudsen JD, Lundgren B, et al. Seminational
surveillance of fungemia in Denmark: notably high
rates of fungemia and numbers of isolates with
reduced azole susceptibility. J Clin Microbiol. 2005;43:4434-40.
http://dx.doi.org/10.1128/JCM.43.9.4434-4440.2005
PMid:16145088
PMCid:PMC1234080
2. Rodloff
C, Koch D, Schaumann R. Epidemiology and antifungal
resistance in invasive candidiasis. Eur J Med Res. 2011;16:187-95.
http://dx.doi.org/10.1186/2047-783X-16-4-187
PMid:21486733
PMCid:PMC3352075
3. Thompson GR 3rd, Patel PK,
Kirkpatrick WR, Westbrook SD, Berg D, Erlandsen J, et
al. Oropharyngeal candidiasis
in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:488-95.
http://dx.doi.org/10.1016/j.tripleo.2009.11.026
PMid:20156694
PMCid:PMC2843789
4. Williams DW, Kuriyama T, Silva S, Malic S,
Lewis MA. Candida biofilms and oral candidosis: treatment and prevention. Periodontol 2000. 2011;55:250-65.
http://dx.doi.org/10.1111/j.1600-0757.2009.00338.x
PMid:21134239
5. Coronado-Castellote L, Jiménez-Soriano Y.
Clinical and microbiological diagnosis of oral candidiasis.
J Clin Exp Dent. 2013;5:e279-e286.
http://dx.doi.org/10.4317/jced.51242
PMid:24455095
PMCid:PMC3892259
6. Byadarahally
Raju S, Rajappa S.
Isolation and identification of Candida from the oral cavity. ISRN Dent. 2011;2011:487921.
PMid: 22111010
7. Aguirre Urizar
JM. Oral Candidiasis. Rev Iberoam Micol. 2002;19:17-21.
PMid:12716225
8. Williams D, Lewis M.
Pathogenesis and treatment of oral candidosis. J Oral Microbiol. 2011 Jan 28;3.
PMid: 21547018
9. Martínez-Beneyto
Y, López-Jornet P, Velandrino-Nicolás
A, Jornet-García V. Use of antifungal agents for oral
candidiasis: results of a national survey. Int J Dent Hyg. 2010;8:47-52.
http://dx.doi.org/10.1111/j.1601-5037.2008.00357.x
PMid:20096082
10. Akpan
A, Morgan R. Oral candidiasis. Postgrad
Med J. 2002;78:455-9.
http://dx.doi.org/10.1136/pmj.78.922.455
PMCid:PMC1742467
11. Manfredi
M, Polonelli L, Aguirre-Urizar
JM, Carrozzo M, McCullough MJ. Urban legends series:
oral candidosis. Oral Dis. 2013;19:245-61.
PMid:22998462
12. Koray
M, Ak G, Kurklu E, Issever H, Tanyeri H, Kulekci G, et al. Fluconazole
and/or hexetidine for management of oral candidiasis associated with denture-induced stomatitis. Oral Dis. 2005;11:309-13.
http://dx.doi.org/10.1111/j.1601-0825.2005.01124.x
PMid:16120118
13. Cross LJ, Williams DW,
Sweeney CP, Jackson MS, Lewis MA, Bagg J. Evaluation
of the recurrence of denture stomatitis and Candida
colonization in a small group of patients who received itraconazole.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97:351-8.
http://dx.doi.org/10.1016/j.tripleo.2003.10.006
PMid:15024360
14. Goins
RA, Ascher D, Waecker N,
Arnold J, Moorefield E. Comparison of fluconazole and
nystatin oral suspensions for treatment of oral candidiasis in infants. Pediatr
Infect Dis J. 2002;21:1165-7.
http://dx.doi.org/10.1097/00006454-200212000-00017
PMid:12506950
15. Epstein JB, Gorsky M, Caldwell J. Fluconazole
mouthrinses for oral candidiasis
in postirradiation, transplant, and other patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:671-5.
http://dx.doi.org/10.1067/moe.2002.122728
PMid:12142873
16. Lefebvre JL, Domenge C; Study Group of Mucositis. A comparative study of the efficacy
and safety of fluconazole oral suspension and amphotericin B oral suspension in cancer patients with mucositis. Oral Oncol. 2002;38:337-42.
http://dx.doi.org/10.1016/S1368-8375(01)00063-X
PMid:12076696
17. Sholapurkar
AA, Pai KM, Rao S.
Comparison of efficacy of fluconazole mouthrinse and clotrimazole mouthpaint in the treatment of oral candidiasis.
Aust Dent J. 2009;54:341-6.
http://dx.doi.org/10.1111/j.1834-7819.2009.01160.x
PMid:20415933
18. Taillandier
J, Esnault Y, Alemanni M. A comparison of fluconazole oral
suspension and amphotericin B oral suspension in
older patients with oropharyngeal candidosis.
Multicentre Study Group. Age Ageing. 2000;29:117-23.
http://dx.doi.org/10.1093/ageing/29.2.117
PMid:10791445
19. Isham
N, Ghannoum MA. Antifungal activity
of miconazole against recent Candida strains. Mycoses. 2010;53:434-7.
http://dx.doi.org/10.1111/j.1439-0507.2009.01728.x
PMid:19531099
20. Pemberton MN, Oliver RJ, Theaker ED. Miconazole oral gel
and drug interactions. Br Dent J. 2004;196:529-31.
http://dx.doi.org/10.1038/sj.bdj.4811224
PMid:15131616
21. Miki A, Ohtani H, Sawada Y. Warfarin and miconazole oral gel interactions: analysis and therapy
recommendations based on clinical data and a pharmacokinetic model. J Clin Pharm Ther. 2011;36:642-50.
http://dx.doi.org/10.1111/j.1365-2710.2010.01229.x
PMid:21143257
22. Collins CD, Cookinham S, Smith J. Management of oropharyngeal
candidiasis with localized oral miconazole
therapy: efficacy, safety, and patient acceptability. Patient Prefer Adherence.
2011;5:369-74.
http://dx.doi.org/10.2147/PPA.S14047
PMid:21845036
PMCid:PMC3150165
23. Vazquez JA, Sobel JD. Miconazole mucoadhesive tablets: a novel delivery system. Clin Infect Dis. 2012;54:1480-4.
http://dx.doi.org/10.1093/cid/cis205
PMid:22495075
24. Czerninski
R, Sivan S, Steinberg D, Gati I, Kagan
L, Friedman M. A novel sustained-release clotrimazole
varnish for local treatment of oral candidiasis.
Clin Oral Investig. 2010;14:71-8.
http://dx.doi.org/10.1007/s00784-009-0275-3
PMid:19404692
25. Oji C, Chukwuneke
F. Evaluation and treatment of oral candidiasis in
HIV/AIDS patients in Enugu, Nigeria. Oral Maxillofac Surg. 2008;12:67-71.
http://dx.doi.org/10.1007/s10006-008-0106-8
PMid:18618163
26. Bensadoun RJ, Daoud J, El Gueddari B, Bastit L, Gourmet R, Rosikon A,
et al. Comparison of the efficacy and safety of miconazole
50-mg mucoadhesive buccal
tablets with miconazole 500-mg gel in the treatment
of oropharyngeal candidiasis:
a prospective, randomized, single-blind, multicenter, comparative, phase III
trial in patients treated with radiotherapy for head and neck cancer. Cancer. 2008;112:204-11.
http://dx.doi.org/10.1002/cncr.23152
PMid:18044772
27. Koks
CH, Crommentuyn KM, Mathôt
RA, Mulder JW, Meenhorst
PL, Beijnen JH. Prognostic factors
for the clinical effectiveness of fluconazole in the
treatment of oral candidiasis in HIV-1-infected
individuals. Pharmacol Res. 2002;46:89-94.
http://dx.doi.org/10.1016/S1043-6618(02)00032-4
PMid:12208126
28. Lyon JP, de Resende MA. Correlation between adhesion,
enzyme production, and susceptibility to fluconazole
in Candida albicans obtained from denture wearers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:632-8.
http://dx.doi.org/10.1016/j.tripleo.2005.12.015
PMid:17052640
29. Oude Lashof
AM, De Bock R, Herbrecht R, de Pauw
BE, Krcmery V, Aoun M, et
al.; EORTC Invasive Fungal Infections Group. An open
multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in
the treatment of cancer patients with oropharyngeal candidiasis. Eur J Cancer.
2004;40:1314-9.
http://dx.doi.org/10.1016/j.ejca.2004.03.003
PMid:15177489
30. Kuriyama
T, Williams DW, Bagg J, Coulter WA, Ready D, Lewis
MA. In vitro susceptibility of oral Candida to seven
antifungal agents.Oral Microbiol
Immunol. 2005;20:349-53.
http://dx.doi.org/10.1111/j.1399-302X.2005.00236.x
PMid:16238594
31. Brito GN, Inocêncio AC,
Querido SM, Jorge AO, Koga-Ito CY. In vitro antifungal
susceptibility of Candida spp. oral isolates from HIV-positive patients and
control individuals. Braz Oral Res. 2011;25:28-33.
http://dx.doi.org/10.1590/S1806-83242011005000001
PMid:21271179
32. Ally R, Schürmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, et al.;Esophageal Candidiasis Study Group. A randomized,
double-blind, double-dummy, multicenter trial of voriconazole
and fluconazole in the treatment of esophageal candidiasis in immunocompromised
patients. Clin Infect Dis. 2001;33:1447-54.
http://dx.doi.org/10.1086/322653
PMid:11577374
33. Khozeimeh
F, Shahtalebi MA, Noori M, Savabi O. Comparative evaluation of ketoconazole
tablet and topical ketoconazole 2% in orabase in treatment of Candida-infected denture stomatitis. J Contemp
Dent Pract. 2010;11:017-24
PMid: 20228983
34. Van Roey
J, Haxaire M, Kamya M, Lwanga I, Katabira E. Comparative
efficacy of topical therapy with a slow-release mucoadhesive
buccal tablet containing miconazole
nitrate versus systemic therapy with ketoconazole in
HIV-positive patients with oropharyngeal candidiasis. J Acquir
Immune Defic Syndr.
2004;35:144-50.
http://dx.doi.org/10.1097/00126334-200402010-00007
PMid:14722446